Current approaches in identifying the FLT3-ITD mutation profile of AML patients are primarily restricted towards cytogenetic assessments—gene karyotyping [8], whole-genome sequencing [9,10], and PCR amplification assays [11,12]—to comprehend the different genotypic changes or mutations present in such cases [13,14]. This evidence concerns the gene FLT3 and acute myeloid leukemia.